November 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Akshat Jain: Asundexian for Recurrent Stroke Prevention

Akshat Jain/Photo: lluh.org

Nov 12, 2026, 10:00

Akshat Jain: Asundexian for Recurrent Stroke Prevention

Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn:

“How do we prevent Re-Stroke ?

Recurrent stroke remains a substantial unmet need despite secondary prevention. five-year recurrence risk can run approximately 10–12 percent in more recent cohorts.

The FDA’s November 9 approval of Sunharbo (asundexian) adds a new option for a defined population: adults with a recent non-cardioembolic ischemic stroke, NIHSS less than or equal to 15, or high-risk TIA. The approved regimen is 50 mg once daily in combination with antiplatelet therapy—not as a replacement for it.

Mechanism: targeting clot amplification

Asundexian is an oral, direct factor XIa inhibitor.

Concerns:

Patient selection and bleeding still matter. The overall bleeding result should not be translated into ‘no increased bleeding risk.’ The FDA reports increased major bleeding in patients older than 75 and during the first 90 days, with gastrointestinal bleeding more common on asundexian.
P-gp/strong CYP3A4 inducers, avoidance in moderate or severe hepatic impairment, and interruption around procedures and thrombolysis.
NOT an atrial-fibrillation indication. OCEANIC-AF was stopped early for lack of efficacy; the secondary-prevention findings cannot be generalized across stroke mechanisms.
(My analysis of the study in the infographic)

The advance is meaningful. Its clinical value will depend on matching the treatment to the stroke mechanism and weighing absolute ischemic benefit against each patient’s bleeding risk.”

Akshat Jain: Asundexian for Recurrent Stroke Prevention